Clinical trial
A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
NCT02831257 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- October 1, 2020
- Enrollment
- 18 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.